Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A.
PRICE/FCF RATIO
N/A
Market Cap
$2.64B
Price/FCF Ratio
39.40
TTM Avg
90.98
3Y Avg
93.90
5Y Avg
93.90
Market Cap
$7.06B
Price/FCF Ratio
95.30
TTM Avg
83.56
3Y Avg
72.25
5Y Avg
72.25
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Shoulder Innovations, Inc. (SI) | $468.68M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $440.37M | 19.87 | 29.66 | 30.20 | 30.39 |
| 23andMe Holding Co. (ME)vs › | $15.31M | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.26B | 5.55 | 5.71 | 7.42 | 14.16 |
| TransMedics Group, Inc. (TMDX)vs › | $2.64B | 39.40 | 90.98 | 93.90 | 93.90 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.76B | 26.49 | 23.61 | 21.73 | 20.30 |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.06B | 95.30 | 83.56 | 72.25 | 72.25 |
| Oscar Health, Inc. (OSCR)vs › | $7.81B | 3.55 | 4.19 | 6.70 | 8.36 |
| Tempus AI, Inc. (TEM)vs › | $8.18B | N/A | N/A | N/A | N/A |
| Insulet Corp. (PODD)vs › | $9.23B | 60.84 | 44.32 | 72.36 | 72.36 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
